Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued on Monday, Marketbeat.com reports. The firm set an “overweight” rating on the stock.

Several other brokerages have also recently issued reports on ATYR. Wells Fargo & Company initiated coverage on Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Trading Down 2.0 %

Atyr PHARMA stock opened at $3.89 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a fifty day simple moving average of $3.31. The company has a market capitalization of $326.53 million, a price-to-earnings ratio of -4.14 and a beta of 1.08. Atyr PHARMA has a 1-year low of $1.39 and a 1-year high of $4.22.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, research analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. lifted its holdings in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.